Premium
Type 1 Diabetes TrialNet–An International Collaborative Clinical Trials Network
Author(s) -
Skyler Jay S.,
Greenbaum Carla J.,
Lachin John M.,
Leschek Ellen,
RafkinMervis Lisa,
Savage Peter,
Spain Lisa
Publication year - 2008
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1447.054
Subject(s) - type 2 diabetes , clinical trial , diabetes mellitus , medicine , endocrinology
Type 1 Diabetes TrialNet is an international consortium of clinical research centers aimed at the prevention or delay of type 1 diabetes (T1D). The fundamental goal of TrialNet is to counter the T1D disease process by immune modulation and/or enhancement of β cell proliferation and regeneration. To achieve this goal, TrialNet researchers are working to better understand the natural history of the disease, to identify persons at risk, and to clinically evaluate novel therapies that balance potential risks and benefits. The particular focus is on studies of preventive measures. In addition, TrialNet evaluates therapies in individuals with newly diagnosed T1D with preserved β cell function to help determine the risk/benefit profile and gain an initial assessment of potential efficacy in preservation of β cell function, so that promising agents can be studied in prevention trials. In addition, TrialNet evaluates methodologies that enhance the conduct of its clinical trials, which includes tests of outcome assessment methodology, the evaluation of surrogate markers, and mechanistic studies laying the foundation for future clinical trials.